Feedback

Browsing by M

Use an asterisk (*) for partial word searches (e.g. pemph*)

177 results found.

1.
2.
3.
4.
5.
6.
Ordering Recommendation:  

May be useful in the assessment of tissue stores. For routine assessment of magnesium deficiency, Magnesium, Plasma or Serum (0020039) is preferred.

7.
8.
Ordering Recommendation:  

Retrospectively diagnose malaria in patients from non-endemic areas with relevant exposure and prior symptoms.

9.
Ordering Recommendation:  

Not a first-line test for malaria screening. Refer to parasite smear (0049025) or malaria rapid screen and Giemsa stain (2001547) for screening and diagnosing acute disease.

10.
Ordering Recommendation:  

Screen for malaria. Patient's travel history is necessary to aid in test interpretation.

11.
12.
Ordering Recommendation:  

Useful as a reasonable indicator of recent, active exposure and provides a modest indicator for distinguishing exposed from non-exposed individuals. May be useful in long-term, low-dose manganese exposure. Whole blood measurements (0099272) are recommended for monitoring potential accumulation with TPN.

13.
Ordering Recommendation:  

May be useful as a reasonable indicator of recent, active exposure and provides a modest indicator for distinguishing exposed from nonexposed individuals. Not recommended for the assessment of manganese body stores. Whole blood measurements (0099272) are recommended for monitoring potential accumulation with TPN.

14.
Ordering Recommendation:  

Limited utility in determining manganese exposure. Whole blood measurements (0099272) are recommended for determining recent, active exposure.

15.
Ordering Recommendation:  

Useful as a reasonable indicator of recent, active exposure and provides a modest indicator for distinguishing exposed from nonexposed individuals. Recommended for monitoring potential accumulation with TPN. Not recommended for detecting long-term, low-dose manganese exposure, refer to Manganese, RBC (2007254).

16.
Ordering Recommendation:  

Initial screening for suspected deficiency in the lectin complement pathway.

17.
18.
Ordering Recommendation:  

Carrier screening or diagnostic testing for maple syrup urine disease type 1B for individuals of Ashkenazi Jewish descent.

19.
20.
Ordering Recommendation:  

This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.

21.
Ordering Recommendation:  

Preferred test to confirm diagnosis when Marfan syndrome (MFS) is strongly suspected by consensus criteria.

22.
Ordering Recommendation:  

Acceptable test to confirm diagnosis for individuals with clinical phenotype of Marfan syndrome (MFS).

23.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

24.
Ordering Recommendation:  

• 1st trimester screening test for trisomy 21 (T21, Down syndrome) and trisomy 18 (T18).
• 2nd trimester screening test for T21, T18, and open neural tube defects.
• Requires nuchal translucency measurement performed by an ultrasonographer certified by the Fetal Medicine Foundation (FMF) or the Nuchal Translucency Quality Review (NTQR).
• Risks provided in both 1st and 2nd trimesters.

25.
Ordering Recommendation:  

Requires a previously submitted 1st trimester specimen, Maternal Screening, Sequential, Specimen #1 (0081293).
• 1st trimester screening test for trisomy 21 (T21, Down syndrome) and trisomy 18 (T18).
• 2nd trimester screening test for T21, T18, and open neural tube defects.
• Requires nuchal translucency measurement performed by an ultrasonographer certified by the Fetal Medicine Foundation (FMF) or Nuchal Translucency Quality Review (NTQR).
• Risks provided in both 1st and 2nd trimesters.

26.
Ordering Recommendation:  

Order this test for PREGNANT FEMALE patients only.  For males or non-pregnant females, refer to Alpha Fetoprotein, Serum (Tumor Marker) (0080428).

27.
Ordering Recommendation:  

Not a recommended aneuploidy screening test due to detection rates that are lower than the Quad screening test. Refer to Maternal Serum Screen, Alpha Fetoprotein, hCG, Estriol, and Inhibin A (0080269).

28.
Ordering Recommendation:  

Second trimester screening test for trisomy 21 (Down syndrome), trisomy 18, and open neural tube defects.

29.
Ordering Recommendation:  

First trimester screening test for trisomy 21 (Down syndrome) and trisomy 18. Does not include alpha fetoprotein for open neural tube defects. Requires nuchal translucency measurement performed by an ultrasonographer certified by the Fetal Medicine Foundation (FMF) or Nuchal Translucency Quality Review (NTQR).

30.
Ordering Recommendation:  

First trimester screening test for trisomy 21 (Down syndrome), trisomy 18, and open neural tube defects. Risks determined using a combination of 1st and 2nd trimester serum markers, with or without 1st trimester nuchal translucency measurement. Risks provided after 2nd trimester specimen is received, Maternal Serum Screening, Integrated, Specimen #2 (0081064).

31.
Ordering Recommendation:  

Requires a previously submitted 1st trimester specimen, Maternal Serum Screening, Integrated, Specimen #1 (0081062). Screens for trisomy 21 (Down syndrome), trisomy 18, and open neural tube defects. Risks determined using a combination of 1st and 2nd trimester serum markers, with or without 1st trimester nuchal translucency measurement. Risks provided after 2nd trimester specimen is received.

32.
Ordering Recommendation:  

Not recommended for well-differentiated liposarcomas lacking atypical cells. Immunohistochemical sensitivity, in this setting, is very low and may yield false-negative results. In these cases, MDM2 FISH (2003016) is recommended. Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

33.
Ordering Recommendation:  

Aid in the differential diagnosis between well-differentiated liposarcoma and benign lipoma in individuals diagnosed with or suspected of having well-differentiated liposarcoma based on tissue morphology.

34.
Ordering Recommendation:  

Aid in the diagnosis of measles infection. Test may not be helpful in patients who have recently received an MMR vaccination.

35.
Ordering Recommendation:  

Not recommended as a stand-alone test unless testing for evidence of antibody production from vaccination.

36.
Ordering Recommendation:  

Not a recommended test. False-positive results will occur due to low incidence of measles in the U.S.

37.
Ordering Recommendation:  

Aid in the diagnosis of acute measles infection. Consider ordering the panel which contains both IgG and IgM antibodies (0050375).

38.
Ordering Recommendation:  

Aid in the diagnosis of measles encephalitis. False-positive results will occur due to low incidence of measles in the U.S.

39.
Ordering Recommendation:  

Culture test for detecting measles virus in specimens other than CSF.

40.
Ordering Recommendation:  

Preferred initial molecular test to confirm a diagnosis or identify carriers of medium chain acyl-CoA dehydrogenase (MCAD) deficiency for individuals with suggestive clinical and/or biochemical findings. To diagnose or rule out MCAD deficiency, refer to 0040033 Acylcarnitine Quantitative Profile, Plasma, 0081170 Acylglycine, Quantitative, Urine, and 0098389 Organic Acids, Urine.

41.
Ordering Recommendation:  

Molecular test to confirm a diagnosis or identify carriers of medium chain acyl-CoA dehydrogenase (MCAD) deficiency for individuals with suggestive clinical and/or biochemical findings. Recommended when 0051205 Medium Chain Acyl-CoA Dehydrogenase (ACADM) 2 Mutations does not identify two causative variants. To diagnose or rule out MCAD deficiency, refer to 0040033 Acylcarnitine Quantitative Profile, Plasma, 0081170 Acylglycine, Quantitative, Urine, and 0098389 Organic Acids, Urine.

42.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

43.
44.
45.
46.
47.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

48.
Ordering Recommendation:  

Confirm suspected hereditary melanoma cancer syndrome in individuals with personal or family history of melanoma. Preferred test for individuals at high risk for hereditary melanoma.

49.
50.
Ordering Recommendation:  

Use to rapidly detect a panel of common viruses, bacteria, and fungi associated with meningitis and encephalitis. Do NOT use as a replacement for CSF bacterial and/or fungal culture and Cryptococcal antigen testing for at-risk patients. A negative result does not exclude a diagnosis of meningitis or encephalitis due to infection.

51.
Ordering Recommendation:  

Monitor patient adherence.

52.
Ordering Recommendation:  

Preferred test to follow-up presumptive results. For general screening, Meperidine Urine Screen with Reflex to Quantitation (2012288) is preferred.

53.
Ordering Recommendation:  

Useful for general screening in contexts of compliance and/or abuse. A screen with reflex testing is the preferred method for ruling out meperidine exposure. For follow-up testing of a presumptive result, Meperidine, Urine Screen with Reflex to Quantitative (2002760) is preferred.

54.
55.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

56.
57.
58.
Ordering Recommendation:  

May be useful in the assessment of acute or chronic elemental or inorganic mercury exposure and/or in monitoring chelation therapy. For the assessment of acute exposure, Mercury, Whole Blood (0099305) is preferred.

59.
Ordering Recommendation:  

May be useful in the assessment of acute or chronic elemental or inorganic mercury exposure and/or in monitoring chelation therapy. For the assessment of acute exposure, Mercury, Whole Blood (0099305) is preferred.

60.
Ordering Recommendation:  

Preferred test for the assessment of acute mercury exposure. For chronic exposure, Mercury, Urine (0025050) is preferred.

61.
Ordering Recommendation:  

Aids in prognostication and therapeutic decisions for neoplasms where amplification has been demonstrated. Screening test for MET gene amplification.

62.
Ordering Recommendation:  

May be used to confirm a diagnosis of metabolic storage disorder in individuals with suggestive clinical and biochemical findings. Not a first-line test for Pompe disease.

63.
Ordering Recommendation:  

Metal ion testing of joint fluid may be complementary to serum testing but is not recommended. Preferred tests for evaluating metal ion release from metal-on-metal joint arthroplasty are Chromium, Serum (0098830) and/or Cobalt, Serum (0025037).

64.
Ordering Recommendation:  

First-line test in suspected pheochromocytoma.

65.
Ordering Recommendation:  

First-line test in suspected pheochromocytoma.

66.
Ordering Recommendation:  

Evaluate if etiology of hypoglycemia is from exposure to metformin. Serum or plasma is the preferred specimen for correlating drug use with hypoglycemia. Order Metformin, Serum or Plasma (0092390).

67.
Ordering Recommendation:  

Preferred test when determining if hypoglycemia is from exposure to metformin. Serum or plasma is the preferred specimen for correlating drug use with hypoglycemia.

68.
Ordering Recommendation:  

Monitor patient adherence.

69.
Ordering Recommendation:  

Preferred test to follow-up presumptive results. For general screening, Methadone Urine Screen with Reflex to Quantitation (2012245) is preferred.

70.
Ordering Recommendation:  

Useful for general screening in contexts of compliance and/or abuse. A screen with reflex testing is the preferred method for ruling out methadone exposure. For follow-up testing of a presumptive result, Methadone and Metabolite, Urine Quantitative (0090362) is preferred.

71.
72.
Ordering Recommendation:  

Monitor exposure to methanol.

73.
74.
75.
Ordering Recommendation:  

Confirm cases of heterozygous or homozygous methemoglobin reductase deficiency.

76.
Ordering Recommendation:  

Monitor methotrexate concentration.

77.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

78.
Ordering Recommendation:  

Determine genetic cause for hyperhomocysteinemia and potential sensitivity to antifolate drugs. Test is not recommended for women who have recurrent pregnancy loss, thrombophilia screening, or neural tube defect risk assessment.

79.
Ordering Recommendation:  

Use to monitor patients with methylmalonic aciduria. Diagnosis of methylmalonic aciduria requires an organic acid panel and appropriate clinical history.

80.
Ordering Recommendation:  

This test is used to evaluate and monitor methylmalonic acidemia.

81.
Ordering Recommendation:  

Use to evaluate vitamin B12 deficiency in individuals with macrocytic or unexplained anemia, or unexplained neurologic disease. Preferred test is 0055662 (vitamin B12 test reflexes to serum methylmalonic acid).

82.
Ordering Recommendation:  

Monitor patient adherence.

83.
Ordering Recommendation:  

Useful for general testing in contexts of compliance and/or abuse. Preferred test to follow-up presumptive results. 

84.
85.
86.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

87.
Ordering Recommendation:  

Aids in therapeutic decisions in individuals with gliomas.

88.
Ordering Recommendation:  

Detect early kidney disease in those with diabetes or other risk factors (eg, hypertension).

89.
Ordering Recommendation:  

First-line screening test for Lynch syndrome. Directs additional molecular diagnostic testing for Lynch syndrome.

90.
Ordering Recommendation:  

Preferred test to diagnose Microsporidia in immunocompromised patients with persistent diarrhea if Encephalitozoon spp (E. intestinalis/E. hellem/E. cuniculi) or E. bieneusi is the suspected infectious agent.

91.
Ordering Recommendation:  

Can be used for follow up of negative PCR result when suspicion of microsporidia infection remains high.

92.
Ordering Recommendation:  

First-line screening test for Lynch syndrome. Directs additional molecular diagnostic testing for Lynch syndrome.

93.
Ordering Recommendation:  

Preferred screening test for Lynch syndrome (LS) in individuals with colorectal cancer. Definitive diagnosis of LS requires additional targeted MMR germline mutation studies. Do not use for endometrial cancer.

94.
Ordering Recommendation:  

Preferred reflex screening test for Lynch syndrome in non-colorectal cancer tumors (eg, endometrial carcinoma) .

95.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

96.
Ordering Recommendation:  

Diagnose mitochondrial disorders resulting from mutations in nuclear genes.

97.
Ordering Recommendation:  

Assess for nuclear gene mutations causing mitochondrial disease.

98.
Ordering Recommendation:  

This is a second tier test and REQUIRES PERMISSION from  ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.

99.
Ordering Recommendation:  

Assess for sequence variants in the mitochondrial genome (mtDNA) causing mitochondrial disorders.

100.
Ordering Recommendation:  

Order when mitochondrial dilated cardiomhyopathy or another mitochondrial disorder, including dilated cardiomyopathy, is suspected.

101.
Ordering Recommendation:  

Comprehensive test to confirm a suspected diagnosis of a mitochondrial disorder.

102.
Ordering Recommendation:  

May be useful in confirming a diagnosis of primary biliary cirrhosis.

103.
Ordering Recommendation:  

Optimize drug therapy.

104.
Ordering Recommendation:  

Distinguishes between Lynch syndrome and sporadic noncolorectal tumors with loss of MLH1.

105.
Ordering Recommendation:  

Diagnose complete or partial molar pregnancy.

106.
107.
Ordering Recommendation:  

Aids in the diagnosis and management of multiple myeloma and related disorders. Use to detect and quantify serum monoclonal protein.

108.
Ordering Recommendation:  

Aids in diagnosis of monoclonal gammopathies.

109.
Ordering Recommendation:  

Aid in diagnosis of combined motor/sensory neuropathy with suspicion for plasma cell dyscrasia or suspicion for other malignancy.

110.
Ordering Recommendation:  

Aid in diagnosis of combined motor/sensory neuropathy when malignancy, other than plasma cell dyscrasia, is suspected.

111.
Ordering Recommendation:  

Aid in diagnosis for motor neuropathy with suspicion for plasma cell dyscrasia.

112.
Ordering Recommendation:  

May be useful when essential thrombocythemia or idiopathic myelofibrosis is suspected in JAK2 V617F-negative individuals.

113.
Ordering Recommendation:  

• Use to monitor previously established MPO/PR-3 antibodies or confirm an IFA ANCA positive test result. Test does not include ANCA testing by IFA.
• For ANCA testing, refer to the available panel tests.
 ○ For the workup of suspected vasculitis, refer to ANCA-Associated Vasculitis Profile (ANCA/MPO/PR-3) Reflex to ANCA Titer (2006480).
 ○ For patients with a history of vasculitis, refer to the ANCA Reflex to Titer and MPO/PR-3 Antibodies (2002068).

114.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

115.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

116.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

117.
Ordering Recommendation:  

Carrier screening or diagnostic testing for mucolipidosis type IV for individuals of Ashkenazi Jewish descent.

118.
Ordering Recommendation:  

Use to evaluate symptomatic patients for mucopolysaccharidoses (MPS). To monitor glycosaminoglycans (GAGs) in patients previously diagnosed with MPS, refer to Mucopolysaccharides, Quantitative, Urine (0081357).

119.
Ordering Recommendation:  

Use to MONITOR glycosaminoglycans (GAGs) in patients previously diagnosed with a mucopolysaccharidosis (MPS). Approval by an ARUP genetic counselor or medical director required BEFORE ordering this test. To screen for MPS, refer to Mucopolysaccharides Screen - Electrophoresis & Quantitation, Urine (0081352).

120.
Ordering Recommendation:  

For research use. Medical Director approval is required to order this test.

121.
Ordering Recommendation:  

Use to monitor heparan sulfate (total disaccharides and nonreducing ends) for  MPS Type 1 patients who are on therapy.

122.
Ordering Recommendation:  

Use to monitor heparan sulfate (total disaccharides and nonreducing ends) excretion for  MPS Type 1 patients who are on therapy.

123.
Ordering Recommendation:  

Use to monitor heparan sulfate (total disaccharides and nonreducing ends) for MPS Type II patients who are on therapy.

124.
Ordering Recommendation:  

Use to monitor heparan sulfate (total disaccharides and nonreducing ends) excretion for MPS Type II patients who are on therapy.

125.
Ordering Recommendation:  

This is a second tier test and REQUIRES PERMISSION from  ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.

126.
Ordering Recommendation:  

Diagnostic testing for multiple endocrine neoplasia type 1. Predictive testing for multiple endocrine neoplasia type 1.

127.
Ordering Recommendation:  

Diagnostic testing for multiple endocrine neoplasia type 1. Predictive testing for multiple endocrine neoplasia type 1.

128.
Ordering Recommendation:  

Diagnostic and predictive testing for multiple endocrine neoplasia type 2.

129.
Ordering Recommendation:  

This is a second tier test and REQUIRES PERMISSION from  ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.

130.
Ordering Recommendation:  

Preferred panel for individuals with clinical phenotype of multiple epiphyseal dysplasia.

131.
Ordering Recommendation:  

Acceptable test for individuals with clinical phenotype of multiple epiphyseal dysplasia. Preferred test is Multiple Epiphyseal Dysplasia Panel, Sequencing and Deletion/Duplication, 6 Genes (2008840).

132.
Ordering Recommendation:  

Aids in risk stratification of individuals with multiple myeloma. Recommended at initial diagnosis and in low-risk individuals at time of relapse.

133.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

134.
Ordering Recommendation:  

Not recommended.

135.
Ordering Recommendation:  

Not recommended.

136.
Ordering Recommendation:  

Not recommended as a stand-alone test unless testing for evidence of antibody production from vaccination.

137.
Ordering Recommendation:  

Aid in the diagnosis of suspected mumps infection.

138.
Ordering Recommendation:  

Culture test for detecting mumps virus in specimens other than CSF.

139.
140.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

141.
Ordering Recommendation:  

Secondary diagnostic testing for patients with generalized or ocular myasthenia gravis and no detectable antibodies to acetylcholine receptor (AChR).

142.
Ordering Recommendation:  

Acceptable diagnostic or predictive test for MUTYH-associated polyposis in Northern European Caucasians. For non-Caucasians, order MUTYH-Associated Polyposis (MUTYH) Sequencing (2006191).

143.
Ordering Recommendation:  

Preferred diagnostic or predictive test for MUTYH-associated polyposis in Northern European Caucasians. For non-Caucasians, order MUTYH-Associated Polyposis (MUTYH) Sequencing (2006191).

144.
Ordering Recommendation:  

Diagnostic or predictive test for MUTYH-associated polyposis. Use if one or no pathogenic variant is found with MUTYH-associated polyposis 2 mutations test.

145.
Ordering Recommendation:  

Facilitates diagnosis of Burkitts lymphoma (BL) and B-cell lymphoma with features intermediate between BL and diffuse large B-cell lymphoma (DLBCL). Detects all MYC rearrangements, including t(8;14), t(2;8), and t(8;22).

146.
Ordering Recommendation:  

Prognostic determination in individuals with neuroblastoma or medulloblastoma.

147.
Ordering Recommendation:  

Panel includes PCR testing to detect M. tuberculosis complex isolates and determine possible resistance to rifampin treatment. Test may be ordered for client-processed specimens. Refer to specimen requirements.

148.
Ordering Recommendation:  

Identify the species of M. tuberculosis complex to species level by comparing genomic deletion patterns; includes testing for M. tuberculosis, M. bovis, M. bovis BCG-vaccine strain, M. africanum, M. microti, M. caprae.

149.
Ordering Recommendation:  

Order for rapid identification of mutations associated with drug resistance for M. tuberculosis treatment. For phenotypic drug susceptibility testing, refer to Antimicrobial Susceptibility, AFB/Mycobacterium tuberculosis Primary Panel (0060347).

150.
Ordering Recommendation:  

Optimize drug therapy and monitor patient adherence.

151.
Ordering Recommendation:  

Identify Mycoplasma hominis in urogential specimens.

152.
Ordering Recommendation:  

May aid in the diagnosis of Mycoplasma pneumoniae in patient with persistent pneumonia that is outside of the expected acute phase.

153.
154.
Ordering Recommendation:  

Panel that combines M. pneumoniae IgG and IgM antibodies is preferred (0050399).

155.
Ordering Recommendation:  

Panel that combines M. pneumoniae IgG and IgM antibodies is preferred (0050399).

156.
Ordering Recommendation:  

Detect M. pneumoniae bacteria.

157.
Ordering Recommendation:  

• Useful in distinguishing lymphoplasmacytic lymphoma (LPL) from other low-grade B-cell lymphoproliferative disorders which may be in the differential diagnosis.
• Use when monitoring patients with LPL diagnosis and previously identified MYD88 L265P mutation.

158.
Ordering Recommendation:  

May be useful in testing for autoimmune neuropathies. Test by itself is not diagnostic and should be used in conjunction with other clinical parameters to confirm disease.

159.
Ordering Recommendation:  

Stand-alone test for autoimmune neuropathies. Test by itself is not diagnostic and should be used in conjunction with other clinical parameters to confirm disease.

160.
Ordering Recommendation:  

Not recommended for the workup of suspected multiple sclerosis. Preferred test is Oligoclonal Band Profile (0080440).

161.
Ordering Recommendation:  

Use in conjunction with conventional cytogenetics for diagnosis, prognosis, and monitoring of minimal residual disease (MRD) in MDS.

162.
Ordering Recommendation:  

Assesses for single gene mutations, including substitutions and insertions and deletions that may have diagnostic, prognostic, and/or therapeutic significance in
• Acute myeloid leukemia
• Myelodysplastic syndromes
• Myeloproliferative neoplasms
• MDS/MPN overlap disorders such as chronic myelomonocytic leukemia

163.
Ordering Recommendation:  

Detects important genomic abnormalities in acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), and MDS/MPN neoplasms that may have diagnostic, prognostic, and/or therapeutic significance:
• Loss/gain of DNA
• Loss of heterozygosity (LOH)
• Single gene mutations (substitutions and small insertions and deletions)

164.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

165.
Ordering Recommendation:  

• When used in conjunction with other autoantibody tests (ANCA, PR-3), may assist in evaluating suspected immune-mediated vasculitis, especially microscopic polyangiitis (MPA).
• May be useful when monitoring MPA disease and/or treatment response.
• Panel tests are available.
 ○ For the workup of suspected vasculitis, refer to ANCA-Associated Vasculitis Profile (ANCA/MPO/PR-3) Reflex to ANCA Titer (2006480).
 ○ For patients with a history of vasculitis, refer to the ANCA Reflex to Titer and MPO/PR-3 Antibodies (2002068).

166.
Ordering Recommendation:  

Determine myeloid lineage in AML per WHO classification. Less sensitive and specific than flow cytometry immunophenotype.

167.
Ordering Recommendation:  

Use to identify cells of myeloid lineage in work up of acute myeloid leukemias and identify myeloperoxidase deficiency in mature neutrophils in immunodeficiency states.

168.
Ordering Recommendation:  

Limited role in the work-up of myeloproliferative neoplasms in the setting of an otherwise optimal cytogenetic study. Aids in exclusion of cryptic BCR-ABL1 rearrangement in chronic myelogenous leukemia and in the exclusion of a PDGFRA abnormality in cases of neoplastic eosinophilia. 

169.
Ordering Recommendation:  

May be useful for the evaluation of autoimmune or inflammatory heart disease especially post cardiotomy or post myocardial infarction syndromes. Negative results do not rule out inflammatory heart disease.

170.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

171.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

172.
Ordering Recommendation:  

Not a stand-alone test. Cardiac troponins [troponin I (0090613) or troponin T (0098803)] are the recommended tests for diagnosis and management of acute coronary syndrome.

173.
174.
Ordering Recommendation:  

Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.

175.
Ordering Recommendation:  

Differential diagnosis of inflammatory myopathies in conjunction with muscle biopsy and clinical presentation. Most useful if general suspicion for inflammatory myopathy exists, including overlap syndrome.

176.
Ordering Recommendation:  

May be useful for differential evaluation of polymyositis, dermatomyositis, necrotizing autoimmune myopathy, or overlap syndromes associated with connective tissue disease.

177.
Ordering Recommendation:  

Differential evaluation of patients with polymyositis/dermatomyositis (PM/DM), necrotizing autoimmune myopathy, connective tissue diseases, and/or overlap syndrome. Most useful if suspicion for inflammatory myopathy is high (eg, antisynthetase syndrome, necrotizing autoimmune myopathy, DM).